You just read:

IO Biotech enters clinical collaboration with MSD evaluating IO102 in combination with KEYTRUDA® (pembrolizumab) in first-line treatment of patients with metastatic non-small cell lung cancer

News provided by

IO Biotech

Mar 12, 2018, 02:00 ET